<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33655556</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2184</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cell proliferation</Title>
          <ISOAbbreviation>Cell Prolif</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.</ArticleTitle>
        <Pagination>
          <StartPage>e13009</StartPage>
          <MedlinePgn>e13009</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e13009</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cpr.13009</ELocationID>
        <Abstract>
          <AbstractText>The sites of targeted therapy are limited and need to be expanded. The FGF-FGFR signalling plays pivotal roles in the oncogenic process, and FGF/FGFR inhibitors are a promising method to treat FGFR-altered tumours. The VEGF-VEGFR signalling is the most crucial pathway to induce angiogenesis, and inhibiting this cascade has already got success in treating tumours. While both their efficacy and antitumour spectrum are limited, combining FGF/FGFR inhibitors with VEGF/VEGFR inhibitors are an excellent way to optimize the curative effect and expand the antitumour range because their combination can target both tumour cells and the tumour microenvironment. In addition, biomarkers need to be developed to predict the efficacy, and combination with immune checkpoint inhibitors is a promising direction in the future. The article will discuss the FGF-FGFR signalling pathway, the VEGF-VEGFR signalling pathway, the rationale of combining these two signalling pathways and recent small-molecule FGFR/VEGFR inhibitors based on clinical trials.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Cell Proliferation Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Guihong</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-1140-5359</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiology Department, Chengdu NO.7 People's Hospital, Chengdu Tumor Hospital, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ding</LastName>
            <ForeName>Zhenyu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biotherapy, State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Yuquan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Xiawei</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0002-6513-6422</Identifier>
            <AffiliationInfo>
              <Affiliation>Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Prolif</MedlineTA>
        <NlmUniqueID>9105195</NlmUniqueID>
        <ISSNLinking>0960-7722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017468">Receptors, Fibroblast Growth Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>62031-54-3</RegistryNumber>
          <NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017468" MajorTopicYN="N">Receptors, Fibroblast Growth Factor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">FGFR/VEGFR inhibitor</Keyword>
        <Keyword MajorTopicYN="N">fibroblast growth factor</Keyword>
        <Keyword MajorTopicYN="N">fibroblast growth factor receptor</Keyword>
        <Keyword MajorTopicYN="N">vascular endothelial growth factor</Keyword>
        <Keyword MajorTopicYN="N">vascular endothelial growth factor receptor</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing financial interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33655556</ArticleId>
        <ArticleId IdType="pmc">PMC8016646</ArticleId>
        <ArticleId IdType="doi">10.1111/cpr.13009</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Nat Rev Clin Oncol. 2017;14:141‐154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27752053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF‐mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open‐label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315‐1327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30219628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non‐small cell lung cancer: a review. JAMA. 2019;322:764‐774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31454018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Loibl S, Gianni L. HER2‐positive breast cancer. Lancet. 2017;389:2415‐2429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27939064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019;16:105‐122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30367139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. New Engl J Med. 2019;381:338‐348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31340094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abou‐Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open‐label, phase 2 study. Lancet Oncol. 2020;21:671‐684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32203698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280:C1358‐C1366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11350730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrara N, Adamis AP. Ten years of anti‐vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385‐403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26775688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Armelin HA. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci U S A. 1973;70:2702‐2706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC427087</ArticleId>
            <ArticleId IdType="pubmed">4354860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem. 1975;250:2515‐2520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1168187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lemmon SK, Bradshaw RA. Purification and partial characterization of bovine pituitary fibroblast growth factor. J Cell Biochem. 1983;21:195‐208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6630303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20:563‐569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15475116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn. 2008;237:18‐27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18058912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Itoh N. Hormone‐like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342:1‐11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2948652</ArticleId>
            <ArticleId IdType="pubmed">20730630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Farrell B, Breeze AL. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem Soc Trans. 2018;46:1753‐1770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6299260</ArticleId>
            <ArticleId IdType="pubmed">30545934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281:15694‐15700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2080618</ArticleId>
            <ArticleId IdType="pubmed">16597617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yeh BK, Igarashi M, Eliseenkova AV, et al. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 2003;100:2266‐2271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151329</ArticleId>
            <ArticleId IdType="pubmed">12591959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005;16:107‐137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15863029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Trueb B. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci. 2011;68:951‐964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21080029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furdui CM, Lew ED, Schlessinger J, Anderson KS. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell. 2006;21:711‐717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16507368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vijayan RS, He P, Modi V, et al. Conformational analysis of the DFG‐out kinase motif and biochemical profiling of structurally validated type II inhibitors. J Med Chem. 2015;58:466‐479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4326797</ArticleId>
            <ArticleId IdType="pubmed">25478866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huhtala MT, Pentikäinen OT, Johnson MS. A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF‐1 leads to an 'electrostatic sandwich' model for heparin binding. Structure. 1999;7:699‐709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10404599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Itoh N, Ohta H, Konishi M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol (Lausanne). 2015;6:154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4586497</ArticleId>
            <ArticleId IdType="pubmed">26483756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guan D, Zhao L, Chen D, Yu B, Yu J. Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state. J Transl Med. 2016;14:63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4774037</ArticleId>
            <ArticleId IdType="pubmed">26931208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kouhara H, Hadari YR, Spivak‐Kroizman T, et al. A lipid‐anchored Grb2‐binding protein that links FGF‐receptor activation to the Ras/MAPK signaling pathway. Cell. 1997;89:693‐702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9182757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lamothe B, Yamada M, Schaeper U, Birchmeier W, Lax I, Schlessinger J. The docking protein Gab1 is an essential component of an indirect mechanism for fibroblast growth factor stimulation of the phosphatidylinositol 3‐kinase/Akt antiapoptotic pathway. Mol Cell Biol. 2004;24:5657‐5666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC480891</ArticleId>
            <ArticleId IdType="pubmed">15199124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Forough R, Weylie B, Patel C, Ambrus S, Singh US, Zhu J. Role of AKT/PKB signaling in fibroblast growth factor‐1 (FGF‐1)‐induced angiogenesis in the chicken chorioallantoic membrane (CAM). J Cell Biochem. 2005;94:109‐116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15517595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dudka AA, Sweet SM, Heath JK. Signal transducers and activators of transcription‐3 binding to the fibroblast growth factor receptor is activated by receptor amplification. Cancer Res. 2010;70:3391‐3401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2887080</ArticleId>
            <ArticleId IdType="pubmed">20388777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thisse B, Thisse C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol. 2005;287:390‐402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16216232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215‐266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4393358</ArticleId>
            <ArticleId IdType="pubmed">25772309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goldfarb M, Schoorlemmer J, Williams A, et al. Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage‐gated sodium channels. Neuron. 2007;55:449‐463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2974323</ArticleId>
            <ArticleId IdType="pubmed">17678857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next‐generation sequencing. Clin Cancer Res. 2016;22:259‐267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26373574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fischbach A, Rogler A, Erber R, et al. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology. 2015;66:639‐649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24898159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miao JL, Zhou JH, Cai JJ, Liu RJ. The association between fibroblast growth factor receptor 1 gene amplification and lung cancer: a meta‐analysis. Arch Med Sci. 2020;16:16‐26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6963147</ArticleId>
            <ArticleId IdType="pubmed">32051701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xie Z, Cheng D, Luo L, et al. Design, synthesis and biological evaluation of 4‐bromo‐N‐(3,5‐dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non‐small cell lung cancer. J Enzyme Inhib Med Chem. 2018;33:905‐919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6009922</ArticleId>
            <ArticleId IdType="pubmed">29734851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318‐332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28303906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cihoric N, Savic S, Schneider S, et al. Prognostic role of FGFR1 amplification in early‐stage non‐small cell lung cancer. Br J Cancer. 2014;110:2914‐2922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4056052</ArticleId>
            <ArticleId IdType="pubmed">24853178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hui R, Pearson A, Cortes J, et al. Lucitanib for the Treatment of HR(+)/HER2(‐) Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clin Cancer Res. 2020;26:354‐363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31619444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Formisano L, Lu Y, Servetto A, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10:1373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6435685</ArticleId>
            <ArticleId IdType="pubmed">30914635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Musolino A, Campone M, Neven P, et al. Phase II, randomized, placebo‐controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(‐) breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19:18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5301372</ArticleId>
            <ArticleId IdType="pubmed">28183331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Quintela‐Fandino M, Apala JV, Malon D, et al. Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. Breast Cancer Res. 2019;21:69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6534834</ArticleId>
            <ArticleId IdType="pubmed">31126332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moelans CB, van Maldegem CMG, van der Wall E, van Diest PJ. Copy number changes at 8p11‐12 predict adverse clinical outcome and chemo‐ and radiotherapy response in breast cancer. Oncotarget. 2018;9:17078‐17092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5908307</ArticleId>
            <ArticleId IdType="pubmed">29682206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fernanda Amary M, Ye H, Berisha F, et al. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo‐adjuvant chemotherapy. Cancer Med. 2014;3:980‐987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4303166</ArticleId>
            <ArticleId IdType="pubmed">24861215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ipenburg NA, Koole K, Liem KS, et al. Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma: a systematic review. Target Oncol. 2016;11:17‐27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4759209</ArticleId>
            <ArticleId IdType="pubmed">26115874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim EK, Cho YA, Koh YW, Shin HA, Cho BC, Yoon SO. Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma. BMC Cancer. 2020;20:348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7181493</ArticleId>
            <ArticleId IdType="pubmed">32326908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bae JM, Wen X, Kim TS, et al. Fibroblast growth factor receptor 1 (FGFR1) amplification detected by droplet digital polymerase chain reaction (ddPCR) is a prognostic factor in colorectal cancers. Cancer Res Treat. 2020;52:74‐84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6962468</ArticleId>
            <ArticleId IdType="pubmed">31096734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012;106:727‐732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3322955</ArticleId>
            <ArticleId IdType="pubmed">22240789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hur JY, Chao J, Kim K, et al. High‐level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathol Res Pract. 2020;216:152878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32089408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Catenacci DV, Tesfaye A, Tejani M, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2‐positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019;15:2073‐2082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31094225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Koole K, van Kempen PM, Swartz JE, et al. Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 2016;5:275‐284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4735780</ArticleId>
            <ArticleId IdType="pubmed">26711175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Geelvink M, Babmorad A, Maurer A, et al. Diagnostic and prognostic implications of FGFR3(high)/Ki67(high) papillary bladder cancers. Int J Mol Sci. 2018;19:2548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6163244</ArticleId>
            <ArticleId IdType="pubmed">30154342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fromme JE, Schmitz K, Wachter A, et al. FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis. Oncotarget. 2018;9:32204‐32218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6114946</ArticleId>
            <ArticleId IdType="pubmed">30181810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R. FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev. 2019;78:1‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31255945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti‐apoptosis and alpha‐fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009;50:118‐127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19008009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153‐158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2712719</ArticleId>
            <ArticleId IdType="pubmed">17344846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Agelopoulos K, Richter GH, Schmidt E, et al. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in ewing sarcoma. Clin Cancer Res. 2015;21:4935‐4946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26179511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA. The progressive fragmentation of the KIT/PDGFRA wild‐type (WT) gastrointestinal stromal tumors (GIST). J Transl Med. 2017;15:113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5442859</ArticleId>
            <ArticleId IdType="pubmed">28535771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Welander J, Łysiak M, Brauckhoff M, Brunaud L, Söderkvist P, Gimm O. Activating FGFR1 mutations in sporadic pheochromocytomas. World J Surg. 2018;42:482‐489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5762800</ArticleId>
            <ArticleId IdType="pubmed">29159601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rand V, Huang J, Stockwell T, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A. 2005;102:14344‐14349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1242336</ArticleId>
            <ArticleId IdType="pubmed">16186508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanizaki J, Ercan D, Capelletti M, et al. Identification of oncogenic and drug‐sensitizing mutations in the extracellular domain of FGFR2. Cancer Res. 2015;75:3139‐3146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26048680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stehbens SJ, Ju RJ, Adams MN, et al. FGFR2‐activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models. J Cell Sci. 2018;131:jcs213678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30002137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Konecny GE, Finkler N, Garcia AA, et al. Second‐line dovitinib (TKI258) in patients with FGFR2‐mutated or FGFR2‐non‐mutated advanced or metastatic endometrial cancer: a non‐randomised, open‐label, two‐group, two‐stage, phase 2 study. Lancet Oncol. 2015;16(6):686‐694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25981814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dodurga Y, Tataroglu C, Kesen Z, Satiroglu‐Tufan NL. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res. 2011;10:86‐95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21264819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang Z, Zhang R, Ge Y, et al. Somatic FGFR3 mutations distinguish a subgroup of muscle‐invasive bladder cancers with response to neoadjuvant chemotherapy. EBioMedicine. 2018;35:198‐203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6154770</ArticleId>
            <ArticleId IdType="pubmed">29941343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hayashi Y, Fujita K, Matsuzaki K, et al. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell‐free DNA in upper tract urothelial carcinoma. Cancer Sci. 2019;110:1771‐1779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6501003</ArticleId>
            <ArticleId IdType="pubmed">30887605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23:18‐20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10471491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weberpals JI, Lo B, Duciaume MM, et al. Vulvar squamous cell carcinoma (VSCC) as two diseases: HPV status identifies distinct mutational profiles including oncogenic fibroblast growth factor receptor 3. Clin Cancer Res. 2017;23:4501‐4510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28377483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liang X, Vacher S, Boulai A, et al. Targeted next‐generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Res. 2018;20:88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6081877</ArticleId>
            <ArticleId IdType="pubmed">30086764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu C, Chen X, Chen D, et al. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies. Int J Biol Macromol. 2019;135:294‐302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31128178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Germline variant FGFR4 p. G388R exposes a membrane‐proximal STAT3 binding site. Nature. 2015;528:570‐574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26675719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cho SH, Hong CS, Kim HN, et al. FGFR4 Arg388 is correlated with poor survival in resected colon cancer promoting epithelial to mesenchymal transition. Cancer Res Treat. 2017;49:766‐777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5512371</ArticleId>
            <ArticleId IdType="pubmed">27857023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Quintanal‐Villalonga Á, Ojeda‐Márquez L, Marrugal Á, et al. The FGFR4‐388arg variant promotes lung cancer progression by N‐cadherin induction. Sci Rep. 2018;8:2394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5799167</ArticleId>
            <ArticleId IdType="pubmed">29402970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pfeifer A, Rusinek D, Żebracka‐Gala J, et al. Novel TG‐FGFR1 and TRIM33‐NTRK1 transcript fusions in papillary thyroid carcinoma. Genes Chromosomes Cancer. 2019;58:558‐566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6594006</ArticleId>
            <ArticleId IdType="pubmed">30664823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kondyli M, Larouche V, Saint‐Martin C, et al. Trametinib for progressive pediatric low‐grade gliomas. J Neurooncol. 2018;140:435‐444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30097824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee JC, Su SY, Changou CA, et al. Characterization of FN1‐FGFR1 and novel FN1‐FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol. 2016;29:1335‐1346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27443518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Verstovsek S, Subbiah V, Masarova L, et al. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. Ann Oncol. 2018;29:1880‐1882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6887683</ArticleId>
            <ArticleId IdType="pubmed">29767670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li F, Peiris MN, Donoghue DJ. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Cytokine Growth Factor Rev. 2020;52:56‐67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31899106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular subtypes of urothelial bladder cancer: results from a meta‐cohort analysis of 2411 tumors. Eur Urol. 2019;75:423‐432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30213523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Di Stefano AL, Picca A, Saragoussi E, et al. Clinical, molecular and radiomic profile of gliomas with FGFR3‐TACC3 fusions. Neuro Oncol. 2020;22:1614‐1624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7690363</ArticleId>
            <ArticleId IdType="pubmed">32413119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Best SA, Harapas CR, Kersbergen A, Rathi V, Asselin‐Labat ML, Sutherland KD. FGFR3‐TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene. 2018;37:6096‐6104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6215478</ArticleId>
            <ArticleId IdType="pubmed">29991799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tamura R, Yoshihara K, Saito T, et al. Novel therapeutic strategy for cervical cancer harboring FGFR3‐TACC3 fusions. Oncogenesis. 2018;7:4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5833787</ArticleId>
            <ArticleId IdType="pubmed">29358619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chew NJ, Nguyen EV, Su SP, et al. FGFR3 signaling and function in triple negative breast cancer. Cell Commun Signal. 2020;18:13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6986078</ArticleId>
            <ArticleId IdType="pubmed">31987043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mizukami T, Sakai K, Naruki S, et al. Identification of a FGFR3‐TACC3 fusion in esophageal cancer. Ann Oncol. 2017;28:437‐438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27771611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9:639‐651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3664927</ArticleId>
            <ArticleId IdType="pubmed">19508171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li X, Wang C, Xiao J, McKeehan WL, Wang F. Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol. 2016;53:155‐167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4875805</ArticleId>
            <ArticleId IdType="pubmed">26768548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murakami M, Sakurai T. Role of fibroblast growth factor signaling in vascular formation and maintenance: orchestrating signaling networks as an integrated system. Wiley Interdiscip Rev Syst Biol Med. 2012;4:615‐629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22930472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suh J, Kim DH, Lee YH, Jang JH, Surh YJ. Fibroblast growth factor‐2, derived from cancer‐associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Mol Carcinog. 2020;59:1028‐1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32557854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu P, Wilhelm K, Dubrac A, et al. FGF‐dependent metabolic control of vascular development. Nature. 2017;545:224‐228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5427179</ArticleId>
            <ArticleId IdType="pubmed">28467822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ronca R, Giacomini A, Rusnati M, Presta M. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin Ther Targets. 2015;19:1361‐1377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26125971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oladipupo SS, Smith C, Santeford A, et al. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc Natl Acad Sci U S A. 2014;111:13379‐13384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4169958</ArticleId>
            <ArticleId IdType="pubmed">25139991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Touat M, Ileana E, Postel‐Vinay S, Andre F, Soria J‐C. Targeting FGFR Signaling in Cancer. Clin Cancer Res. 2015;21:2684‐2694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26078430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Porta R, Borea R, Coelho A, et al. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol. 2017;113:256‐267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28427515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu F‐T, Li N‐G, Zhang Y‐M, et al. Recent advance in the development of novel, selective and potent FGFR inhibitors. Eur J Med Chem. 2020;186:111884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31761386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med. 1971;285:1182‐1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4938153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983‐985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6823562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A. 1997;94:7192‐7197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC23789</ArticleId>
            <ArticleId IdType="pubmed">9207067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822‐7835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15520188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela‐Arispe ML. Processing of VEGF‐A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 2005;169:681‐691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171712</ArticleId>
            <ArticleId IdType="pubmed">15911882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 2010;21:687‐690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828956</ArticleId>
            <ArticleId IdType="pubmed">20185770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9‐22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9872925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669‐676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Simons M, Gordon E, Claesson‐Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611‐625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27461391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Parker MW, Xu P, Li X, Vander Kooi CW. Structural basis for selective vascular endothelial growth factor‐A (VEGF‐A) binding to neuropilin‐1. J Biol Chem. 2012;287:11082‐11089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3322888</ArticleId>
            <ArticleId IdType="pubmed">22318724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mac Gabhann F, Popel AS. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem. 2007;128:125‐139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2711879</ArticleId>
            <ArticleId IdType="pubmed">17442480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Flk‐1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A. 2005;102:1076‐1081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC545830</ArticleId>
            <ArticleId IdType="pubmed">15644447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Olsson AK, Dimberg A, Kreuger J, Claesson‐Welsh L. VEGF receptor signalling ‐ in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359‐371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16633338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor‐2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19:2003‐2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17658244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deng Y, Zhang X, Simons M. Molecular controls of lymphatic VEGFR3 signaling. Arterioscler Thromb Vasc Biol. 2015;35:421‐429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4304921</ArticleId>
            <ArticleId IdType="pubmed">25524775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005;109:227‐241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16104843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325‐340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921900</ArticleId>
            <ArticleId IdType="pubmed">29508855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu Y, Zhong Z, Huber J, et al. Anti‐vascular endothelial growth factor receptor‐1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res. 2006;12:6573‐6584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17085673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002;1:219‐227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12086857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor‐induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841‐844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7683111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581‐611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15294883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 2004;350:2335‐2342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15175435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733‐4740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19720927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pujade‐Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum‐resistant recurrent ovarian cancer: The AURELIA open‐label randomized phase III trial. J Clin Oncol. 2014;32:1302‐1308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24637997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. New Engl J Med. 2014;370:734‐743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4010094</ArticleId>
            <ArticleId IdType="pubmed">24552320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312‐3318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19451442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine‐refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double‐blind, phase 3 trial. Lancet. 2014;384:319‐328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4366116</ArticleId>
            <ArticleId IdType="pubmed">24768112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19:177‐189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30575405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol. 2013;6:459‐473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3808572</ArticleId>
            <ArticleId IdType="pubmed">24179482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krupitskaya Y, Ramucirumab WHA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR‐2 for the potential treatment of cancer. Curr Opin Invest Drugs. 2000;10:597‐605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19513949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Casanovas O, Hicklin DJ. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late‐stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16226705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haibe Y, Kreidieh M, El Hajj H, et al. Resistance mechanisms to anti‐angiogenic therapies in cancer. Front Oncol. 2020;10:221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7056882</ArticleId>
            <ArticleId IdType="pubmed">32175278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bai Y, Bai L, Zhou J, Chen H, Zhang L. Sequential delivery of VEGF, FGF‐2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis. Cell Immunol. 2018;323:19‐32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29111157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xue L, Greisler HP. Angiogenic effect of fibroblast growth factor‐1 and vascular endothelial growth factor and their synergism in a novel in vitro quantitative fibrin‐based 3‐dimensional angiogenesis system. Surgery. 2002;132:259‐267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12219021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Murakami M, Nguyen LT, Hatanaka K, et al. FGF‐dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011;121:2668‐2678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3223828</ArticleId>
            <ArticleId IdType="pubmed">21633168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cao R, Ji H, Feng N, et al. Collaborative interplay between FGF‐2 and VEGF‐C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A. 2012;109:15894‐15899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3465417</ArticleId>
            <ArticleId IdType="pubmed">22967508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ichikawa K, Watanabe Miyano S, Minoshima Y, Matsui J, Funahashi Y. Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti‐VEGF therapy. Sci Rep. 2020;10:2939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7031295</ArticleId>
            <ArticleId IdType="pubmed">32076044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ma J, Song Y, Shou J, et al. Anlotinib for patients with metastatic renal cell carcinoma previously treated with one vascular endothelial growth factor receptor‐tyrosine kinase inhibitor: a phase 2 trial. Front Oncol. 2020;10:664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7221023</ArticleId>
            <ArticleId IdType="pubmed">32457838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Angevin E, Lopez‐Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19:1257‐1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23339124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open‐label, multicentre trial. Lancet Oncol. 2015;16:1473‐1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26482279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512‐519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5357473</ArticleId>
            <ArticleId IdType="pubmed">27704266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okusaka T, Otsuka T, Ueno H, et al. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci. 2016;107:1791‐1799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5198968</ArticleId>
            <ArticleId IdType="pubmed">27627050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Im JH, Buzzelli JN, Jones K, et al. FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat Commun. 2020;11:4064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7426415</ArticleId>
            <ArticleId IdType="pubmed">32792542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front Immunol. 2018;9:978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5943566</ArticleId>
            <ArticleId IdType="pubmed">29774034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Katoh M. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole‐body homeostasis (Review). Int J Mol Med. 2016;38:3‐15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4899036</ArticleId>
            <ArticleId IdType="pubmed">27245147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death‐1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer. 2020;9:338‐357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7325120</ArticleId>
            <ArticleId IdType="pubmed">32647635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Holmström TH, Moilanen AM, Ikonen T, et al. ODM‐203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity. Mol Cancer Ther. 2019;18:28‐38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30301864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi‐targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6146601</ArticleId>
            <ArticleId IdType="pubmed">30231931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han B, Li K, Wang Q, et al. Effect of anlotinib as a third‐line or further treatment on overall survival of patients with advanced non‐small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569‐1575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6248083</ArticleId>
            <ArticleId IdType="pubmed">30098152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun Y, Du F, Gao M, et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer. Thyroid. 2018;28:1455‐1461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30142994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft‐tissue sarcoma. Clin Cancer Res. 2018;24:5233‐5238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29895706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu Y, Hall T, Eathiraj S, Wick MJ, Schwartz B, Abbadessa G. In‐vitro and in‐vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anticancer Drugs. 2017;28:503‐513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5404396</ArticleId>
            <ArticleId IdType="pubmed">28240679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Papadopoulos KP, El‐Rayes BF, Tolcher AW, et al. A Phase 1 study of ARQ 087, an oral pan‐FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 2017;117:1592‐1599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5729432</ArticleId>
            <ArticleId IdType="pubmed">28972963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mazzaferro V, El‐Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion‐positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165‐171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6342954</ArticleId>
            <ArticleId IdType="pubmed">30420614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Porta C, Giglione P, Liguigli W, Paglino C. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol. 2015;11:39‐50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25572783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693‐3702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23658459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693‐3702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23658459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hahn NM, Bivalacqua TJ, Ross AE, et al. A phase II trial of dovitinib in bcg‐unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12–157. Clin Cancer Res. 2017;23:3003‐3011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5462889</ArticleId>
            <ArticleId IdType="pubmed">27932416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third‐line targeted treatment of patients with metastatic renal cell carcinoma: an open‐label, randomised phase 3 trial. Lancet Oncol. 2014;15:286‐296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5719485</ArticleId>
            <ArticleId IdType="pubmed">24556040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheng AL, Thongprasert S, Lim HY, et al. Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2016;64:774‐784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27082062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Watanabe Miyano S, Yamamoto Y, Kodama K, et al. E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models. Mol Cancer Ther. 2016;15:2630‐2639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27535969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Koyama T, Shimizu T, Iwasa S, et al. First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci. 2020;111:571‐579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7004556</ArticleId>
            <ArticleId IdType="pubmed">31797489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine‐refractory thyroid cancer. New Engl J Med. 2015;372:621‐630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25671254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nishio M, Horai T, Horiike A, et al. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non‐small‐cell lung cancer. Br J Cancer. 2013;109:538‐544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3738144</ArticleId>
            <ArticleId IdType="pubmed">23860537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first‐line or second‐line setting (EPOC1706): an open‐label, single‐arm, phase 2 trial. Lancet Oncol. 2020;21:1057‐1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32589866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‐inferiority trial. Lancet. 2018;391:1163‐1173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29433850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open‐label, single‐arm, phase 2 trial. Lancet Oncol. 2019;20:711‐718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30922731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shitara K. Lenvatinib and pembrolizumab simultaneous combination study (Lenva+Pembro). 2018. https://ClinicalTrialsgov/show/NCT03609359. Accessed August 1, 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bello E, Colella G, Scarlato V, et al. E‐3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011;71:1396‐1405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21212416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xie Q, Chen H, Ai J, et al. Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer. Acta Pharmacol Sin. 2017;38:1533‐1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5672066</ArticleId>
            <ArticleId IdType="pubmed">28795691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Soria JC, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014;25:2244‐2251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25193991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Lett. 2015;358:59‐66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4450873</ArticleId>
            <ArticleId IdType="pubmed">25527450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nogueira Pangrazi E, da Silva RF, Kido LA, Montico F, Cagnon VHA. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial‐stromal interaction balance. Cell Biol Int. 2018;42:153‐168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28980742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Patwardhan PP, Musi E, Schwartz GK. Preclinical evaluation of nintedanib, a triple angiokinase inhibitor, in soft‐tissue sarcoma: potential therapeutic implication for synovial sarcoma. Mol Cancer Ther. 2018;17:2329‐2340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30166401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bahleda R, Hollebecque A, Varga A, et al. Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours. Br J Cancer. 2015;113:1413‐1420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4815889</ArticleId>
            <ArticleId IdType="pubmed">26512876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paluri R, Madan A, Li P, et al. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2019;83:551‐559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6490179</ArticleId>
            <ArticleId IdType="pubmed">30603797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dizon DS, Sill MW, Schilder JM, et al. A phase II evaluation of nintedanib (BIBF‐1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014;135:441‐445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4373614</ArticleId>
            <ArticleId IdType="pubmed">25312396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy‐naive patients with advanced malignant pleural mesothelioma (LUME‐Meso): a double‐blind, randomised, placebo‐controlled phase 3 trial. Lancet Respir Med. 2019;7:569‐580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31103412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Van Cutsem E, Yoshino T, Lenz HJ, et al. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME‐Colon 1): a phase III, international, randomized, placebo‐controlled study. Ann Oncol. 2018;29:1955‐1963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6158765</ArticleId>
            <ArticleId IdType="pubmed">30010751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Norden AD, Schiff D, Ahluwalia MS, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high‐grade gliomas. J Neurooncol. 2015;121:297‐302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25338318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Secord AA, McCollum M, Davidson BA, et al. Phase II trial of nintedanib in patients with bevacizumab‐resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Gynecol Oncol. 2019;153:555‐561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30929823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bronte G, Passiglia F, Galvano A, et al. Nintedanib in NSCLC: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:188‐197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872248</ArticleId>
            <ArticleId IdType="pubmed">27239237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caglevic C, Grassi M, Raez L, et al. Nintedanib in non‐small cell lung cancer: from preclinical to approval. Ther Adv Respir Dis. 2015;9:164‐172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25855060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Y, Peng X, Guan X, et al. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors. Eur J Med Chem. 2017;126:122‐132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27750146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper‐CVAD with ponatinib as first‐line therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: long‐term follow‐up of a single‐centre, phase 2 study. The Lancet Haematology. 2018;5:e618‐e627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30501869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cortes JE, Kim DW, Pinilla‐Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome‐positive leukemias. New Engl J Med. 2013;369:1783‐1796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3886799</ArticleId>
            <ArticleId IdType="pubmed">24180494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lipton JH, Chuah C, Guerci‐Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open‐label, phase 3 trial. Lancet Oncol. 2016;17:612‐621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27083332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72:2045‐2056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22369928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aggarwal C, Redman MW, Lara PN Jr, et al. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway‐activated stage IV squamous cell lung cancer (lung‐MAP substudy). J Thorac Oncol. 2019;14:1847‐1852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6901020</ArticleId>
            <ArticleId IdType="pubmed">31195180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Van Cutsem E, Bang YJ, Mansoor W, et al. A randomized, open‐label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28:1316‐1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29177434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chae YK, Hong F, Vaklavas C, et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI‐MATCH trial (EAY131) Subprotocol W. J Clin Oncol. 2020;38:2407‐2417
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7367548</ArticleId>
            <ArticleId IdType="pubmed">32463741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Futami T, Okada H, Kihara R, et al. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19‐Expressing Hepatocellular Carcinoma. Mol Cancer Ther. 2017;16:68‐75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27837028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kikuchi A, Suzuki T, Nakazawa T, et al. ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance. Cancer Sci. 2017;108:236‐242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5329164</ArticleId>
            <ArticleId IdType="pubmed">27885740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamamoto N, Ryoo BY, Keam B, et al. A phase 1 study of oral ASP5878, a selective small‐molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies. Invest New Drugs. 2020;38:445‐456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31041575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bolos D, Finn RS. Systemic therapy in HCC: lessons from brivanib. J Hepatol. 2014;61:947‐950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24972045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Park JW, Finn RS, Kim JS, et al. Phase II, open‐label study of brivanib as first‐line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17:1973‐1983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21349999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Finn RS, Kang YK, Mulcahy M, et al. Phase II, open‐label study of brivanib as second‐line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2090‐2098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22238246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Siu LL, Shapiro JD, Jonker DJ, et al. Phase III randomized, placebo‐controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy‐refractory, wild‐type K‐RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol. 2013;31:2477‐2484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23690424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology. 2014;60:1697‐1707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24996197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK‐PS study. J Clin Oncol. 2013;31:3509‐3516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23980090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first‐line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK‐FL study. J Clin Oncol. 2013;31:3517‐3524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23980084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose‐escalation study of JNJ‐42756493, an oral pan‐fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33:3401‐3408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26324363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs. 2018;36:424–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28965185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bahleda R, Italiano A, Hierro C, et al. Multicenter phase I study of erdafitinib (JNJ‐42756493), oral pan‐fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25:4888‐4897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31088831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Roubal K, Myint ZW, Kolesar JM. Erdafitinib: a novel therapy for FGFR‐mutated urothelial cancer. Am J Health Syst Pharm. 2020;77:346‐351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32073123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011;10:2200‐2210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21900693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Michael M, Bang YJ, Park YS, et al. A phase 1 Study of LY2874455, an oral selective pan‐FGFR inhibitor, in patients with advanced cancer. Target Oncol. 2017;12:463‐474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28589492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wei M, Peng X, Xing L, et al. Design, synthesis and biological evaluation of a series of novel 2‐benzamide‐4‐(6‐oxy‐N‐methyl‐1‐naphthamide)‐pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors. Eur J Med Chem. 2018;154:9‐28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29775937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Koyama N, Saito K, Nishioka Y, et al. Pharmacodynamic change in plasma angiogenic proteins: a dose‐escalation phase 1 study of the multi‐kinase inhibitor lenvatinib. BMC Cancer. 2014;14:530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4223557</ArticleId>
            <ArticleId IdType="pubmed">25047123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spallanzani A, Orsi G, Andrikou K, et al. Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2018;18:1069‐1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30220234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25:5449‐5457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30944124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou X, Hou W, Gao L, Shui L, Yi C, Zhu H. Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality. Front Oncol. 2020;10:1321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7403214</ArticleId>
            <ArticleId IdType="pubmed">32850419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharp MCD. Safety and efficacy of lenvatinib (E7080/MK‐7902) in combination with pembrolizumab (MK‐3475) versus lenvatinib as first‐line therapy in participants with advanced hepatocellular carcinoma (MK‐7902‐002/E7080‐G000‐311/LEAP‐002). https://ClinicalTrialsgov/show/NCT037135932020. Accessed October 22, 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>
Inc. E. Lenvatinib/everolimus or lenvatinib/pembrolizumab versus sunitinib alone as treatment of advanced renal cell carcinoma (CLEAR). 2016. https://ClinicalTrialsgov/show/NCT02811861. Accessed June 23, 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>
Missiaglia E, Selfe J, Hamdi M, et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer. 2009;48:455‐467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19235922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chudasama P, Renner M, Straub M, et al. Targeting fibroblast growth factor receptor 1 for treatment of soft‐tissue sarcoma. Clin Cancer Res. 2017;23:962‐973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27535980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reis‐Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12:6652‐6662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17121884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee HJ, Seo AN, Park SY, et al. Low prognostic implication of fibroblast growth factor family activation in triple‐negative breast cancer subsets. Ann Surg Oncol. 2014;21:1561‐1568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24385208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone‐resistant prostate cancer. Clin Cancer Res. 2003;9:5271‐5281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14614009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim HS, Lee SE, Bae YS, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget. 2015;6:2562‐2572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4385871</ArticleId>
            <ArticleId IdType="pubmed">25537505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schäfer MH, Lingohr P, Sträßer A, et al. Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma. Hum Pathol. 2015;46:1488‐1495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26239623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawamata F, Patch AM, Nones K, et al. Copy number profiles of paired primary and metastatic colorectal cancers. Oncotarget. 2018;9:3394‐3405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5790471</ArticleId>
            <ArticleId IdType="pubmed">29423054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495‐501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4523082</ArticleId>
            <ArticleId IdType="pubmed">25719666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pu XH, Ye Q, Yang J, et al. Low‐level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population. Hum Pathol. 2018;76:100‐109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29514108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29:2013‐2023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2852518</ArticleId>
            <ArticleId IdType="pubmed">20101236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018;654:77‐86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29454091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bisping G, Kropff M, Wenning D, et al. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma‐derived interleukin‐6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood. 2006;107:2079‐2089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16278310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hall TG, Yu Y, Eathiraj S, et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. PLoS One. 2016;11:e0162594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5023172</ArticleId>
            <ArticleId IdType="pubmed">27627808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4177084</ArticleId>
            <ArticleId IdType="pubmed">25295214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hilberg F, Tontsch‐Grunt U, Baum A, et al. Triple angiokinase inhibitor nintedanib directly inhibits tumor cell growth and induces tumor shrinkage via blocking oncogenic receptor tyrosine kinases. J Pharmacol Exp Ther. 2018;364:494‐503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6040086</ArticleId>
            <ArticleId IdType="pubmed">29263244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan‐BCR‐ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation‐based resistance. Cancer Cell. 2009;16:401‐412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2804470</ArticleId>
            <ArticleId IdType="pubmed">19878872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang XF, Dai Y, Peng X, et al. SOMCL‐085, a novel multi‐targeted FGFR inhibitor, displays potent anticancer activity in FGFR‐addicted human cancer models. Acta Pharmacol Sin. 2018;39:243‐250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5800477</ArticleId>
            <ArticleId IdType="pubmed">28905937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res. 2011;17:5299‐5310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3156934</ArticleId>
            <ArticleId IdType="pubmed">21622725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ‐42756493 (Erdafitinib), a functionally selective small‐molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16:1010‐1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28341788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han B, Li K, Zhao Y, et al. Anlotinib as a third‐line therapy in patients with refractory advanced non‐small‐cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118:654‐661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5846072</ArticleId>
            <ArticleId IdType="pubmed">29438373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhou AP, Bai Y, Song Y, et al. Anlotinib versus sunitinib as first‐line treatment for metastatic renal cell carcinoma: A randomized phase II clinical trial. Oncologist. 2019;24:e702‐e708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6693716</ArticleId>
            <ArticleId IdType="pubmed">30902918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schäfer N, Gielen GH, Kebir S, et al. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J Cancer Res Clin Oncol. 2016;142:1581‐1589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27100354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Powles T, Foreshew SJ, Shamash J, et al. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. Eur J Cancer. 2014;50:2057‐2064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24908540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011;17:7451‐7461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21976540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lim SM, Chung WY, Nam KH, et al. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer. 2015;51:1588‐1595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26070683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dillon PM, Petroni GR, Horton BJ, et al. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2017;23:4138‐4145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5540767</ArticleId>
            <ArticleId IdType="pubmed">28377480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121:2612‐2617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25903089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laurie SA, Hao D, Leighl NB, et al. A phase II trial of dovitinib in previously‐treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 2017;104:65‐69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28213002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Escudier B, Grünwald V, Ravaud A, et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res. 2014;20:3012‐3022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24691021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Milowsky MI, Dittrich C, Duran I, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3‐mutated or FGFR3 wild‐type advanced urothelial carcinoma. Eur J Cancer. 2014;50:3145‐3152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25457633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose‐escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011;17:2528‐2537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21372218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106:1598‐1604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3349182</ArticleId>
            <ArticleId IdType="pubmed">22516948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takahashi S, Kiyota N, Yamazaki T, et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019;15:717‐726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30638399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22:44‐53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26311725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vergote I, Powell MA, Teneriello MG, et al. Second‐line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020;156:575‐582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31955859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamamoto N, Kenmotsu H, Goto K, et al. An open‐label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first‐line chemotherapy. Cancer Chemother Pharmacol. 2018;82:685‐694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6132853</ArticleId>
            <ArticleId IdType="pubmed">30073583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schliemann C, Gerss J, Wiebe S, et al. A phase I dose escalation study of the triple angiokinase inhibitor nintedanib combined with low‐dose cytarabine in Elderly patients with acute myeloid leukemia. PLoS One. 2016;11:e0164499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5055288</ArticleId>
            <ArticleId IdType="pubmed">27716819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U. Phase II open‐label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol. 2013;111:205‐212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23184145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han JY, Kim HY, Lim KY, Hwangbo B, Lee JS. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer. 2016;96:108‐112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27133759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non‐small‐cell lung cancer (LUME‐Lung 1): a phase 3, double‐blind, randomised controlled trial. Lancet Oncol. 2014;15:143‐155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24411639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
du Bois A, Kristensen G, Ray‐Coquard I, et al. Standard first‐line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO‐OVAR 12): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet Oncol. 2016;17:78‐89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26590673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tojo A, Kyo T, Yamamoto K, et al. Ponatinib in Japanese patients with Philadelphia chromosome‐positive leukemia, a phase 1/2 study. Int J Hematol. 2017;106:385‐397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28444644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jain P, Kantarjian H, Jabbour E, et al. Ponatinib as first‐line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. The Lancet Haematology. 2015;2:e376‐383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4587395</ArticleId>
            <ArticleId IdType="pubmed">26436130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paik PK, Shen R, Berger MF, et al. A Phase Ib open‐label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers. Clin Cancer Res. 2017;23:5366‐5373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5600836</ArticleId>
            <ArticleId IdType="pubmed">28615371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saka H, Kitagawa C, Kogure Y, et al. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Invest New Drugs. 2017;35:451‐462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5502072</ArticleId>
            <ArticleId IdType="pubmed">28070720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jonker DJ, Rosen LS, Sawyer MB, et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol. 2011;22:1413‐1419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3139984</ArticleId>
            <ArticleId IdType="pubmed">21131369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chan JK, Deng W, Higgins RV, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;146:554‐559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728988</ArticleId>
            <ArticleId IdType="pubmed">28728751</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
